Valneva SE Announces Documentation for Shareholder Meeting and Shares Corporate Update

Saint-Herblain, France, June 5, 2024 - Valneva SE VALN, a specialty vaccine company, today made an announcement regarding the availability of the documentation for its up-and-coming Combined General Meeting. This essential meeting for stakeholders is scheduled to take place on June 26, 2024, at 2:00 p.m. local time. The VALN stock is publicly traded, offering investors the opportunity to participate in the niche market of prophylactic vaccine development, particularly focusing on infectious diseases that currently have no adequate preventive solutions.

Upcoming Combined General Meeting for Shareholders

Valneva SE has made available the necessary documentation to its shareholders in preparation for the Combined General Meeting. This pivotal gathering will allow investors to engage with the company's management and deliberate on various crucial matters laid out in the agenda. All shareholders of record are encouraged to review the documentation ahead of the meeting in order to cast informed votes on the presented resolutions.

Valneva SE's Strategic Focus

As a prominent player in the vaccine industry, VALN is devoted to addressing some of the most pressing health concerns caused by infectious diseases. With a strategic headquarters in Saint-Herblain, France, Valneva SE emphasizes its dedication towards the development and marketing of vaccines that provide exceptional responses to global health emergencies. This commitment is reflected in the company's ongoing projects and research initiatives, which aim to benefit public health on a worldwide scale.

Valneva, Shareholder, Meeting